Abstract
Hypertension increases the risk of reinfarction and sudden death in post-myocardial infarction (MI) patients. The same s true of coexisting left ventricular hypertrophy. Fortunately, these two risk factors may be modified by pharmacotherapy. In this article, Dr Boden describes the complementary use of beta blockers and selected calcium channel blockers for secondary prevention after acute MI, particularly in the subset of patients who also have hypertension.
MeSH terms
-
Adrenergic beta-Antagonists / pharmacology
-
Adrenergic beta-Antagonists / therapeutic use*
-
Calcium Channel Blockers / pharmacology
-
Calcium Channel Blockers / therapeutic use*
-
Cardiomegaly / complications
-
Cardiomegaly / drug therapy*
-
Cardiomegaly / mortality
-
Clinical Protocols / standards
-
Comorbidity
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Hypertension / mortality
-
Myocardial Infarction / complications*
-
Myocardial Infarction / mortality
-
Myocardial Infarction / prevention & control
-
Prognosis
-
Proportional Hazards Models
-
Recurrence
-
Risk Factors
-
Survival Rate
Substances
-
Adrenergic beta-Antagonists
-
Calcium Channel Blockers